Based on the enterprise purpose of "dedicating high-quality products and creating human health", the company has invested 60 million yuan in product research and development since 2002, and cooperated with more than a dozen famous domestic drug research and development bases such as the R&D Center of the Ministry of Health, the Institute of Pharmacy of the Chinese Academy of Sciences and Xi Jiaotong University to develop and produce nearly 30 national-level new drugs such as the national first-class antibacterial drug "Kuitai" gatifloxacin sodium chloride injection and "Kuitai" plus. Compound dextran 40 injection, a third-class national new drug; National four-class new drugs "Oroto" ornidazole sodium chloride injection, "Oroto" ornidazole capsules, secnidazole tablets and other products. At present, a product pattern with anti-infection, cardiovascular and cerebrovascular diseases and nutrient solution has been initially formed, and the sales network has covered 3/kloc-0 provinces, municipalities and autonomous regions nationwide. In recent years, sales have maintained an annual growth rate of more than 40%.
Based on the strong professional advantages in the field of large infusion production, the company has formulated the development strategy of "making large infusion bigger and stronger". In 2006, it invested 30 million yuan to build two advanced non-PVC soft bag large infusion production lines, which passed the national certification in September 2007, and the first batch of products are planned to be put on the market in the first half of 2008.
Wanlong Pharmaceutical has gone through 13 years. The birthday of 13 is a milestone and a new starting point. A new starting point, opportunities and challenges coexist, and hopes and difficulties coexist. Bandung people will not be afraid of difficulties, be determined to move forward, and strive to open up new horizons and create new glories.